Saturday, 16 March 2013

AAN week Begins

Neuros are congregating in San Diego USA for the Annual AAN meeting. March 16-23



  Will Prof G have time to Post?

View abstracts here

6 comments:

  1. Could MS be caused by one or more pathogens whether viral or bacterial that causes a genetic mutation in the HLA(human leukocyte Antigen) located in the HLA-DR2 gene which attacks the neuropeptide Hypocretin or its receptors orexin A & B or OX1 and OX2? This in turns down regulates the human homeostasis causing demyelation?

    Or, could individuals who already have a predisposition because of this mutated gene expression, develop MS because of a pathogenic trigger whether viral/bacterial/fungal?

    ReplyDelete
    Replies
    1. This is not really a mutation but a normal variant of the HLA (the bodies identifier) which no doubt has value in helping humans spot infections of some description. This variant would be part of the predisposition, which is probably involved in relation to the biralbacterila/fungal trigger.

      Delete
  2. I guess this might article regarding generic Copaxone might be of interest for you / the blog.

    http://link.springer.com/article/10.1007%2Fs11094-013-0864-y

    Analysis of reasons for the impossibility of creating Copaxone generics

    G. Ya. Shvarts,
    G. V. Ramenskaya

    Look Inside Get Access

    The characteristics of Copaxone (glatiramer acetate, GA), an immunomodulating drug for the treatment of the serious autoimmune CNS disease multiple sclerosis, were presented. GA is the acetate of a mixture of synthetic polypeptides of various lengths composed of the natural amino acids L-glutamine, L-alanine, L-tyrosine, and L-lysine in stable molecular ratios that are prepared in definite and strictly controlled laboratory and manufacturing conditions. The polymerization reaction is carried out by addition of separate monomers and not whole peptide chains. The average length of the heterogeneous peptides in GA varies from 20 to 200 amino acids. The amino-acid sequence of the GA polypeptides is controlled to a large extent by the polymerization reaction conditions. The average molecular weight of the GA polypeptides varies in the range 5000 – 9000 Da. The majority of GA polypeptides have a molecular-weight distribution of approximately 2,500 – 20,000 Da. An analysis of the materials regarding features of the chemical structure, pharmacological and toxicological properties of GA and its analogs (glatiramoids) indicated that creating GA generics is at present practically impossible.
    Translated from Khimiko-Farmatsevticheskii Zhurnal, Vol. 46, No. 11, pp. 24 – 29, November, 2012.

    ReplyDelete
    Replies
    1. There are indeed companies that are trying to create so called copaxone generics. When the patents of Glaterimer run out they are waiting. The question is whether these generics need trials to prove efficacy because as you say there are differences even between batches of Glaterimer acetate product. No doubt Teva will be trying as hard as possible to make sure competitors have as hard a time as possible generating generics.

      I bite my lip in relation to this aspect.

      Delete
  3. Will Prof G have time to post...Looks like the answer is No

    ReplyDelete
    Replies
    1. Not a chance; simply too many meetings and too little time for sleep or play.

      Delete

Please note that all comments are moderated and any personal or marketing-related submissions will not be shown.